Is HealthCare Global Enterprises Limited a good investment? HealthCare Global Enterprises Limited (HCG.NS) is currently trading at 527.70 INR. Market analysts have a consensus price target of 761.14 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 399.85. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: HealthCare Global Enterprises Limited is expected to release its next earnings report on May 22, 2026. The market consensus estimate for Forward EPS is 9.36.
No, it does not currently pay a dividend.
HealthCare Global Enterprises Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be May 22, 2026. The company currently has a trailing EPS of 1.33.
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, translational and nuclear medicine, oncodermatology, anaesthesiology, paediatric and gynaecologic oncology, orthopaedic oncology, uro-oncology, infectious diseases, gastrointestinal and thoracic oncology, breast surgical oncology, clinical pharmacology, and pain and palliative services. In addition, the company operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. Further, it provides oncology diagnostics services, including biomarker and translational research, and clinical research services under the Triesta Sciences brand; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion